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NADPH OXIDASE 2 (NOX2): A KEY TARGET OF OXIDATIVE 1 
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ABSTRACT      1 
Oxidative stress represents an imbalance between the production of reactive 2 
oxygen species (ROS) and the cellular antioxidant system. Increased levels of 3 
oxidative stress contribute to the development of atherosclerosis that eventually 4 
leads to thrombosis; a principle cause of heart attacks and strokes. Thrombosis is 5 
a consequence of platelet activation and aggregate formation within the circulation. 6 
Platelet ROS are mostly generated by reduced nicotinamide adenine dinucleotide 7 
phosphate (NADPH) oxidase. NOX2 is an isoform from NADPH oxidase expressed 8 
in platelets and an important regulator of platelet activation‐associated thrombosis. 9 
The present article aims to highlight the relative contribution of NOX2 as a key 10 
target of different platelet activation pathways and antiplatelet treatment. 11 
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INTRODUCTION 1 
Cardiovascular diseases (CVD) continue to be a substantial health-care burden. 2 
The recent decrease in cardiovascular mortality in high-income countries has been 3 
associated with a rise in the numbers of aging patients living with CVD. Oxidative 4 
stress is associated with several CVD, including hypertension, heart failure, stroke, 5 
diabetes and atherosclerosis. The development of atherosclerosis in the arterial 6 
circulation underlies the progress of thrombotic disease. Platelets are critical for 7 
hemostasis, but under oxidative conditions, play also a key role in the process of 8 
thrombosis (1).   9 
Oxidative stress represents an imbalance between reactive oxygen species (ROS) 10 
production and ROS removal by the cellular antioxidant defense system, whereby 11 
they mediate damage to cell structures, including lipids, membranes, proteins and 12 
DNA  (2).  Oxidative stress and ROS production have long been regarded as a key 13 
pathophysiological mediator that ultimately leads to CVD. Chronic and acute 14 
overproduction of ROS under pathophysiologic conditions is integral in the 15 
development of CVD. In this context, ROS also participate in a wide variety of 16 
pathophysiology processes such as elevated platelet activation (3).  17 
Platelet activation is a complex process that involves different cellular signaling 18 
pathways. Experimental and clinical studies support the pivotal role played by ROS 19 
in elevated platelet activation. Collagen and thrombin-induced platelet aggregation 20 
is associated with production of ROS, which acts as a second messenger by 21 
stimulating the arachidonic acid metabolism and phospholipase C pathway (4-6). In 22 
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addition, ROS plays a key role in agonists (collagen, thrombin, or calcium 1 
ionophore [A23187])-induced glycoprotein (GP) Ibα ectodomain shedding (7). 2 
Although ROS modulate signaling pathway during platelet adhesion and activation 3 
does not individually activate GPIIb/IIIa receptors (8).  4 
In platelets, ROS are mostly generated by reduced nicotinamide adenine 5 
dinucleotide phosphate (NADPH) oxidase; an enzyme complex that was primarily 6 
described in phagocytes. NADPH oxidase of the NOX family are important 7 
enzymatic sources of ROS (9). Seven isoforms of NOX have been described in 8 
mammals and the NOX2 isoform is expressed in platelets, where it induces 9 
superoxide anion (O2-) production (10). The present article aims to highlight the 10 
relative contribution of NOX2 as a key target of different platelet activation 11 
pathways and antiplatelet treatment.  12 
OXIDATIVE STRESS AND PLATELET ACTIVATION  13 
Platelets have a dynamic functional repertoire with participation in  hemostasis and 14 
thrombosis, which is dependent on a complex balance of activatory and inhibitory 15 
signaling pathways (11). Platelets play a key role in the prevention of excessive 16 
blood loss through the formation of a thrombus. After vascular injury, platelets 17 
rapidly adhere to activated endothelial cells and/or subendothelial matrix proteins 18 
such as collagen and von Willebrand factor through receptor–ligand interactions. 19 
Subsequently, activated platelets and the release of granular molecules such as 20 
adenosine diphosphate (ADP), are essential for stable thrombus formation at the 21 
site of vascular injury. However, excessive platelet activation and hyper-reactive 22 
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platelets are thought to contribute to atherothrombosis that can lead to myocardial 1 
infarction and stroke (12, 13). 2 
Platelets are equipped with an effective enzymatic antioxidant system, the most 3 
important of which are superoxide dismutase (SOD), catalase (CAT), glutathione 4 
peroxidase (GPX), glutathione transferase (GST) and glutathione reductase 5 
(GSSG-R). However, the imbalance between the formation of ROS and 6 
antioxidative system efficiency contributes to the pathogenesis of thrombotic 7 
disease, through elevated intracellular levels of ROS, which mediate elevated 8 
platelet activation (14).  9 
In platelets, ROS including superoxide anion, hydroxyl radicals or hydrogen 10 
peroxide act as second messengers to modulate platelets via calcium mobilization, 11 
nitric oxide (NO) inactivation and through the interaction with arachidonic acid to 12 
enable the formation of isoprostanes. Notably, elevated levels of isoprostanes are 13 
associated with systemic and local platelet activation (15, 16).  14 
During activation, platelets generate ROS through several intracellular sources 15 
such as NADPH oxidase, cyclooxygenases, uncoupled endothelial nitric oxide 16 
synthase (eNOS), xanthine oxidase (XO) and mitochondrial respiration (6, 17-19). 17 
However, data concerning expression eNOS by platelets remain controversial. 18 
Gambaryan et al., demonstrate that human and mouse platelets do not 19 
contain eNOS proteins or mRNA (20). 20 
NADPH OXIDASE AND PLATELET ACTIVATION 21 
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Recently, it has become evident that NADPH oxidase activity is functionally 1 
expressed not only in phagocytes but also in various cell types, including platelets. 2 
Platelet NADPH oxidase is a multicomponent protein complex assembled by the 3 
cellular subunits p47phox, p67phox, and the membrane-bound proteins p22phox and 4 
gp91phox, which together with the small GTPase Rac1/2 associate to form the 5 
active enzyme complex (21).  6 
Platelet-associated NADPH oxidase mediates a thrombogenic phenotype. Growing 7 
data from experimental and clinical studies provide evidence that NADPH oxidase 8 
is implicated in altered platelet activation via superoxide anion production (22, 23). 9 
Collagen activation induces NADPH oxidase-dependent superoxide anion release 10 
in platelets, which in turn enhances the availability of released ADP, resulting in 11 
increased thrombus formation (24). Indeed, NADPH oxidase inhibitors have been 12 
shown to reduce platelet aggregation and thrombus formation on collagen under 13 
high shear (25, 26). Meanwhile, inhibition with apocynin (NOX2 inhibitor that 14 
prevents serine phosphorylation of p47phox and blocks its association with gp91phox) 15 
reduces platelet adhesion in patients with advanced atherosclerosis (27). 16 
Seven distinct members of the NADPH oxidase family have been characterized, of 17 
which four (namely NOX1, 2, 4 and 5) may have cardiovascular functions (28). 18 
Among the enzymes generating ROS, NOX1 and NOX2 play differential roles in 19 
different platelet activation pathways. Thus, using knockout mice, NOX1(-/Y) 20 
platelets showed selective defects in thrombin- or thromboxane A2 analog 21 
U46619-mediated platelet activation.  22 
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NOX2 AND PLATELET ACTIVATION  1 
NOX2 has been implicated in various aspects of CVD. It is suggested to play a role 2 
in favouring the occurrence of atrial fibrillation (AF) after cardiac surgery via 3 
formation of ROS, and in peripheral artery disease patients, ROS generated by 4 
NOX2 contribute to reduce flow-mediated dilation (29, 30). In addition, NOX2 5 
promotes carotid plaque rupture and stroke occurrence (31). Meanwhile, 6 
administration of an antioxidant (propionyl-L-carnitine) is able to improve arterial 7 
dilatation via NOX2 inhibition (32).  8 
Platelet-leukocyte interactions on activated endothelial cells play an important role 9 
during microvascular occlusion under oxidative stress conditions. Platelet NOX2-10 
produced ROS regulated P-selectin exposure upon agonist stimulation and the 11 
ligand-binding function of GPIbα, which contribute to the pathology of hepatic 12 
ischemia/reperfusion injury during vascular inflammation (33). Furthermore the 13 
activation of NOX2 on platelets is increased in heart failure, likely as a 14 
consequence of the underlying inflammatory processes (34). 15 
NOX2 is expressed in platelets and the megakaryocyte cell-line (MEG01). In 16 
human platelets the enzymatic activity of NOX2 believed to be an important source 17 
of ROS in platelets (10, 21, 35). NOX2-generated superoxide anion  is rapidly 18 
converted into the longer-lasting and membrane diffusible hydrogen peroxide, 19 
which is the major ROS contributing to pathological signaling through oxidative 20 
modification of lipids and proteins (24, 36). This is evidenced by the almost absent 21 
ROS production by platelets from patients with hereditary deficiency of NOX2 (37, 22 
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38). The platelet NOX2 enzyme consists of membrane subunits (p22phox and 1 
gp91phox) and cytosolic components (p47phox, p67phox and p40phox), which together 2 
with the small GTPase rac1/2 associate to form the active enzyme complex (Figure 3 
1) (21, 36, 39). Upon activation, binding of Rac1 GTPase to p67phox plays a 4 
critical role in NOX2 activation by facilitating the assembly of the NOX2 enzyme 5 
complex. Meanwhile, inhibition of Rac1 GTPase by NSC23766 or gene targeting 6 
on Rac1 GTPase clearly demonstrated that Rac1 is essential for agonist induced 7 
ROS generation in platelets (40, 41).  Therefore, NOX2 could be a key target of 8 
different platelet activation pathways. The pathways modulated by platelet NOX2 9 
are illustrated in Figure 1.  10 
a) Activation pathways of platelet NOX2 11 
NOX2 can be activated by sCD40L/CD40L, collagen/GPVI or ox-LDL/CD36.   12 
sCD40L/CD40L. CD40 ligand (CD40L) is expressed and functional on platelets, 13 
and plays a pivotal role in atherosclerosis (42).  CD40L is cryptic in unstimulated 14 
platelets but is rapidly unveiled on the platelet surface after platelet stimulation 15 
(43). Platelet production of superoxide anion plays a key role in CD40L expression 16 
and platelets from patients with an inherited deficiency of gp91phox  exhibited 17 
defects in superoxide anion  production and  CD40L expression (36). In addition, 18 
such patients exhibit very low levels of sCD40L in unstimulated platelets and no 19 
changes following platelet stimulation (36). This suggests that the surface-20 
expressed CD40L is subsequently cleaved over a period of minutes to hours, 21 
generating a soluble fragment termed sCD40L that remains trimeric. Indeed, it has 22 
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been calculated that >95% of circulating sCD40L originates from platelets (43). 1 
Elevated levels of sCD40L enhance platelet activation, aggregation, and platelet-2 
leukocyte conjugation, and increase stimulation-induced platelet increase of ROS 3 
through activation of Akt and p38 MAP kinase signaling pathways (44). In this 4 
context, NOX2 is an important mediator in sCD40L-induced ROS generation. 5 
Consistent with this, apocynin inhibits the increase of ROS induced by sCD40L 6 
(44). Moreover, plasma levels of sCD40L are dependent on the expression of 7 
NOX2. Additionally sCD40L is reduced in gp91phox defective patients and is 8 
expressed at higher levels in obese women where NOX2 is upregulated (45).  9 
Collagen/GPVI. GPVI is a membrane glycoprotein unique to platelets and has 10 
been identified as a physiological receptor for collagen (46). NOX2 subunit p47phox 11 
and binding partner tumor necrosis factor receptor associated factor (TRAF) 4 are 12 
associated with the cytoplasmic tails of GPVI, and link ROS production to NOX2 13 
function (47).  TRAF4 is immediately upstream of a proline-rich sequence that 14 
binds the tyrosine kinase Lyn. Lyn is involved in phosphorylation of the 15 
immunoreceptor tyrosine-based activation motif (ITAM) motif within the Fc receptor 16 
(FcR) Ɣ-chain (in complex with GPVI), leading to activation of Syk and the Syk-17 
dependent signaling pathway involving SLP76, Bruton´s tyrosine kinase (BTK), 18 
phosphatidylinositol 3-kinase (PI3K), phospholipase C (PLC) and protein kinase C 19 
(PKC). GPVI stimulation culminates in affinity up-regulation of GPIIb/IIIa allowing 20 
fibrinogen binding and thus, platelet aggregation and thrombus formation (47).  21 
NOX2 (-/-) platelets showed reduced ROS generation and potent inhibition of CRP-22 
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induced platelet activation. Also, a partial inhibition of thrombin-1 
induced platelet activation was observed (22).  2 
ox-LDL/CD36. Oxidized lipids are markers of oxidative stress, important mediators 3 
of atherosclerosis and activators of platelets. Metabolic syndrome in obese 4 
patients, diabetic or non-diabetic, is associated with increased oxidative stress in 5 
low-density lipoprotein (ox-LDL), which triggers platelet activation (48, 49). In 6 
addition, a low HDL phenotype, both in CVD patients and healthy subjects, is 7 
associated with increase of lipid peroxidation and platelet activation (50).   8 
A number of studies have suggested that ox-LDL may bind to and activate platelets 9 
(51-53). Platelet CD36, a member of the Type 2 scavenger receptor family, is a 10 
multiligand pattern recognition receptor that recognizes specific oxidized 11 
phospholipids, molecules expressed on microbial pathogens, apoptotic cells, and 12 
cell-derived microparticles. Elevated platelet CD36 expression may contribute to 13 
increased risk of thrombo-embolism. The interactions of platelet CD36 with 14 
endogenous oxidized lipids play a crucial role in the prothrombotic phenotype (54). 15 
CD36 binds ox-LDL and induces platelet hyperactivity via generation of ROS. The 16 
synthesis of ROS by ox-LDL/CD36 required Src-family kinases, PKC-dependent 17 
phosphorylation and activation of NOX2, which is blocked by CD36 inhibitors, 18 
NOX2 inhibitor (gp91ds-tat) and is absent in NOX2(-/-) mice (51).  Therefore 19 
platelet activation via specific ox-LDL/CD36 is mediated by NOX2 activation (55). 20 
Moreover, at pathophysiological levels in hyperlipidemic patients, oxidized choline 21 
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glycerophospholipids are able to bind and promoted platelet activation via CD36 1 
(54). 2 
b) Downstream signaling pathway of platelet NOX2 activation 3 
Downstream of NOX2, ROS production occurs, thromboxane A2 levels are 4 
increased and P-selectin expression and intracellular Ca2+ release occur. 5 
Intracellular Ca2+ release modulates an early stage of cell activation such as 6 
granular secretion. In addition, platelet NOX2-derived ROS, have been shown to 7 
mediate the oxidation of sulfhydryl groups in GPIbα and enhance its ligand-binding 8 
function with von Willebrand factor on endothelial cells and the integrin αMβ2 on 9 
monocytes (33, 56). 10 
The 8-iso-prostaglandin F2 alpha (8-iso-PGF2α) is a stable isoprostane and 11 
reliable marker of oxidative stress in vivo (57). Elevated levels of 8-iso-PGF2α in 12 
CVD are associated with systemic and local platelet activation and notably, platelet 13 
NOX2 contributes to the formation of 8-iso-PGF2α (45, 58). In children with 14 
hypercholesterolemia, platelet gp91phox and urinary isoprostanes levels are 15 
increased (38). Platelet 8-iso-PGF2α formed as a consequence of NOX2 activation 16 
contributes to platelet recruitment via activation of GPIIb/IIIa (39). 17 
CLINICAL SIGNIFICANCE OF PLATELET NADPH 18 
Excessive ROS production by NADPH oxidase causes cellular stress, leading to 19 
various diseases, including thrombotic conditions. Therefore, a complete 20 
understanding of the function of platelet-derived NADPH oxidase is important to 21 
direct the role of this enzyme towards antiplatelet therapy.  22 
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Patients with the clinical syndrome of chronic granulomatous disease (CGD) have 1 
increased propensity to infection with certain bacteria. Importantly, investigation of 2 
X-linked CGD patients have provided a clinical model to study the role of NADPH  3 
in the atherothrombosis and its clinical sequelae. In this context, CGD patients with 4 
gp91phox or p47phox deficiency have an impaired inactivation of NO would result in 5 
enhanced NO bioavailability and arterial dilatation. In addition, these patients had 6 
significant reduction of carotid intima–media thickness with a similar reduction 7 
detected in both p47phox- and gp91phox-deficient subtypes. In contrast, the 8 
prevalence of coronary arterial calcification was similar between patients with CGD 9 
and controls.  These finding suggests that loss of NADPH function prevents or 10 
retards atherosclerosis progression even in a disease such as CGD (59). 11 
Platelets from NOX2(-/-) patients displayed defective arterial thrombosis but 12 
bleeding time was not affected in CGD patients,  suggesting an important role for 13 
platelet NOX2 in thrombosis but not in hemostasis (22, 55). Thus platelet 14 
aggregation of platelets obtained from CGD patients was significantly reduced in 15 
association with impairment of 8-iso-PGF2α production. In addition, NOX2(-/-) 16 
platelets showed potent inhibition of collagen-related peptide (CRP, a GPVI 17 
selective agonist)-induced platelet activation, and also showed partial inhibition of 18 
thrombin-induced platelet activation. Consistent with these findings, platelets from 19 
gp91phox-deficient (catalytic core of NOX2) patients showed an almost complete 20 
absence of superoxide anion and CD40L expression, but collagen-induced platelet 21 
aggregation was similar to that of healthy subjects (36). 22 
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ROS formed by NOX activity play a critical role in CVD, indeed, the C242T 1 
polymorphism of the NOX  gene is a pathogenetic risk factor for CVD (60). 2 
Tamoxifen is effective in the prevention and treatment of breast cancer, but its use 3 
is associated with an increased risk of thrombosis. Incubation of platelets with the 4 
active metabolites of tamoxifen increases stimulation-dependent superoxide 5 
anion release through a NADPH oxidase-dependent mechanism and therefore 6 
may cause thrombosis (61).  7 
Up to one-third of serious vascular events in high-risk patients are attributable to 8 
aspirin resistance. In platelets from aspirin-resistant patients, both NADPH-driven 9 
superoxide anion production, and expression of gp91phox and p67phox subunits 10 
tended to increase. Maximal aggregation of aspirin resistant platelets to collagen 11 
and epinephrine was significantly decreased by NADPH oxidase inhibitors 12 
(diphenylene iodonium and apocynin), whereas they had no effect in aspirin 13 
sensitive platelets. These data suggest a potential use of NADPH oxidase 14 
inhibitors in the occurrence of thrombosis in high-risk cardiac patients (56, 62).  15 
Since NOX2 is expressed in tissues throughout the cardiovascular system, and 16 
plays an important role in platelet activation in thrombosis but not hemostasis, 17 
platelet NOX2 inhibition might represent a promising strategy to prevent 18 
thrombosis in both aspirin resistant and tamoxifen treated patients (22, 34, 63).  As 19 
shown in Table 1, platelet NOX2 inhibitors could be used in the prevention of CVD 20 
via inhibition of platelet activation. The main mechanisms inhibitors of NOX2 are 21 
compounds which bind to p67phox, p47phox or Rac1; thereby preventing assembly of 22 
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the active NOX2 complex (64-69).  These findings may provide a rationale for the 1 
use of perhexiline and statins to prevent platelet activation via inhibition of NOX2.   2 
CONCLUSION  3 
There is abundant evidence that oxidative stress, caused by an excess of ROS, 4 
regulates several components of thrombosis, including platelet activation. NOX2 is 5 
an isoform from NADPH oxidase expressed in platelets and is likely one of the 6 
important sources of oxidative stress. Platelet NOX2 is a key target of different 7 
platelet activation pathways, and may represent an alternative or additional 8 
therapeutic target to prevent thrombosis associated with oxidative stress. 9 
Practice Points: 10 
NOX2 plays a prominent role in platelet activation. 11 
NOX2 can be activated by sCD40L/CD40L, collagen/GPVI or ox-LDL/CD36.   12 
Perhexiline (an approved prescription drug for angina) and statins (atorvastatin and 13 
rosuvastatin) used clinically present inhibition of NOX2 and antiplatelet activity 14 
Research Agenda: 15 
Clinical value of platelet NOX2 inhibitors.  16 
Experimental studies on side effects of platelet NOX2 inhibitors. 17 
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Table 1. Inhibitors of platelet NOX2 with antiplatelet activity.  1 
Drugs NOX2 
inhibition 
Antiplatelet activity 
Phox-I1 Phox-I1 binds to p67phox and 
abrogates Rac1 binding.  
 
Platelets treated with Phox-I inhibited CRP, 
thrombin or U46619 induced ROS generation, P-
selectin expression, ATP secretion and 
aggregation. 
Celastrol  Celastrol bound to SH3 
domain of p47phox and 
disrupted the binding of the 
proline rich region of p22phox. 
Celastrol inhibited ADP or thrombin-induced 
expression of P-selectin and GPIIb/IIIa, and ADP-
stimulated platelet fibrinogen binding.  
Ebselen  Ebselen interrupted the 
translocation of p47phox to 
membranes. 
In aspirin-treated human platelets ebselen 
inhibited agonist-triggered increase in intracellular 
calcium. 
NOX2ds-tat  NOX2ds-tat binds to p47phox, 
thereby preventing assembly 
of the active NOX2 complex. 
NOX2ds-tat inhibited platelet oxidative stress and 
function including platelet ROS, NOX2 activation, 
8-iso-PGF2α formation and platelet recruitment. 
Suramin  Inhibited biochemical NOX2 
activity.  
Suramin inhibited platelet aggregation induced by 
thrombin, PAF, ALPA, or arachidonic acid 
and increase in intracellular calcium. 
Perhexiline  Inhibited biochemical NOX2 
activity. 
Perhexiline increase NO/cGMP in SAP and ACS 
patients. 
Statins  
(atorvastatin  
and  
rosuvastatin )  
Reduce the expression of 
Rac1, p22phox and gp91phox. 
Inhibited platelet activation and isoprostanes, 
TXA2 and platelet O2- release.  
ACS: acute coronary syndromes, ADP: adenosine diphosphate, ALPA:  alkyllysophosphatidic acid, ATP: adenosine 2 
triphosphate, CRP: collagen-related peptide, cGMP: cyclic guanosine monophosphate, NO: nitric oxide, PAF: platelet 3 
activating factor, ROS: reactive oxygen species, SAP: stable angina pectoris, TXA2: thromboxane A2, 8-iso-PGF2α: 8-iso-4 
prostaglandin F2 alpha. 5 
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 1 
Figure 1. Activation and downstream signaling pathways of platelet NOX2. 2 
Continuous lines: activation and dotted line: inhibition. 3 
